tetano
Editor, Senior Moderator
Vaccine
. 2024 Sep 5;42(24):126269.
doi: 10.1016/j.vaccine.2024.126269. Online ahead of print. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
Irene Hoxie[SUP] 1 [/SUP], Kirill Vasilev[SUP] 1 [/SUP], Jordan J Clark[SUP] 1 [/SUP], Kaitlyn Bushfield[SUP] 1 [/SUP], Benjamin Francis[SUP] 1 [/SUP], Madhumathi Loganathan[SUP] 1 [/SUP], John D Campbell[SUP] 2 [/SUP], Dong Yu[SUP] 2 [/SUP], Lizheng Guan[SUP] 3 [/SUP], Chunyang Gu[SUP] 3 [/SUP], Shufang Fan[SUP] 3 [/SUP], S Mark Tompkins[SUP] 4 [/SUP], Gabriele Neumann[SUP] 3 [/SUP], Yoshihiro Kawaoka[SUP] 5 [/SUP], Florian Krammer[SUP] 6 [/SUP]
Affiliations
Recombinant influenza virus neuraminidase (NA) is a promising broadly protective influenza vaccine candidate. However, the recombinant protein alone is not sufficient to induce durable and protective immune responses and requires the coadministration of immunostimulatory molecules. Here, we evaluated the immunogenicity and cross-protective potential of a recombinant influenza virus N2 neuraminidase vaccine construct, adjuvanted with a toll-like receptor 9 (TLR9) agonist (CpG 1018® adjuvant), and alum. The combination of CpG 1018 adjuvant and alum induced a balanced and robust humoral and T-cellular immune response against the NA, which provided protection and reduced morbidity against homologous and heterologous viral challenges in mouse and hamster models. This study supports Syrian hamsters as a useful complementary animal model to mice for pre-clinical evaluation of influenza virus vaccines.
Keywords: Influenza; Neuraminidase; Neuraminidase inhibition; TLR9 agonist; Vaccine.
. 2024 Sep 5;42(24):126269.
doi: 10.1016/j.vaccine.2024.126269. Online ahead of print. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
Irene Hoxie[SUP] 1 [/SUP], Kirill Vasilev[SUP] 1 [/SUP], Jordan J Clark[SUP] 1 [/SUP], Kaitlyn Bushfield[SUP] 1 [/SUP], Benjamin Francis[SUP] 1 [/SUP], Madhumathi Loganathan[SUP] 1 [/SUP], John D Campbell[SUP] 2 [/SUP], Dong Yu[SUP] 2 [/SUP], Lizheng Guan[SUP] 3 [/SUP], Chunyang Gu[SUP] 3 [/SUP], Shufang Fan[SUP] 3 [/SUP], S Mark Tompkins[SUP] 4 [/SUP], Gabriele Neumann[SUP] 3 [/SUP], Yoshihiro Kawaoka[SUP] 5 [/SUP], Florian Krammer[SUP] 6 [/SUP]
Affiliations
- PMID: 39241354
- DOI: 10.1016/j.vaccine.2024.126269
Recombinant influenza virus neuraminidase (NA) is a promising broadly protective influenza vaccine candidate. However, the recombinant protein alone is not sufficient to induce durable and protective immune responses and requires the coadministration of immunostimulatory molecules. Here, we evaluated the immunogenicity and cross-protective potential of a recombinant influenza virus N2 neuraminidase vaccine construct, adjuvanted with a toll-like receptor 9 (TLR9) agonist (CpG 1018® adjuvant), and alum. The combination of CpG 1018 adjuvant and alum induced a balanced and robust humoral and T-cellular immune response against the NA, which provided protection and reduced morbidity against homologous and heterologous viral challenges in mouse and hamster models. This study supports Syrian hamsters as a useful complementary animal model to mice for pre-clinical evaluation of influenza virus vaccines.
Keywords: Influenza; Neuraminidase; Neuraminidase inhibition; TLR9 agonist; Vaccine.